Nesvacumab Biosimilar - Research Grade

Human

Angiopoietin 2

>1mg/ml

Human IgG1

Zansecimab Biosimilar - Research Grade (ICH5290)

https://www.imgt.org/mAb-DB/

ICH3002

O15123

Blue ice

This is a research-grade, unconjugated non-therapeutic recombinant analog of nesvacumab, a fully human IgG1 monoclonal antibody directed against human Angiopoietin-2 (ANGPT2/Ang-2; UniProt O15123). It reproduces the target specificity of the originator investigational drug, which was developed as an anti-angiogenic agent (studied alone and in combination with anti-VEGF approaches in oncology and ophthalmology). Supplied for research use only, it is not the clinical product and is not intended for human or veterinary use. The format is well suited to in-vitro and preclinical laboratory work: as a positive control or reference antibody in Ang-2 binding and neutralization assays, for benchmarking biosimilar or novel anti-Ang-2 candidates, for ADC/bispecific development workflows, and for studying Ang-2 signaling in the Tie2 axis. It is available at low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and in bulk milligram-to-gram quantities to support scaled and reproducible experiments. Because it is delivered unconjugated, users can label, format, or engineer it as their assay demands require. Guidance for ichorbio to review. Angiopoietin-2 (ANGPT2/Ang-2) is a secreted glycoprotein ligand of the Tie2 (TEK) receptor tyrosine kinase and a key regulator of vascular remodeling. It is stored in endothelial Weibel-Palade bodies and released rapidly upon activation, acting largely as a context-dependent antagonist of the stabilizing ligand Angiopoietin-1. By competing for Tie2, Ang-2 destabilizes quiescent, mature vessels and sensitizes the endothelium to angiogenic and inflammatory cues, priming vessels for sprouting in the presence of VEGF or for regression in its absence. Ang-2 is strongly upregulated at sites of active angiogenesis, tumor vasculature, and vascular inflammation, and its dysregulation is implicated in tumor growth, metastasis, and ocular neovascular and edematous disease. This antagonistic, destabilizing role, and the cross-talk between the Ang/Tie2 and VEGF pathways, underlies the therapeutic interest in neutralizing Ang-2.

ANGPT2, ANG2

Detects human Ang-2. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Nesvacumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.